Ns Pharma, Inc.

Ns Pharma, Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

NS Pharma, Inc. (NSP) located in Paramus New Jersey is a subsidiary of Nippon Shinyaku Co., Ltd. Founded in 1999 in the United States, NSP is engaged in clinical studies and partnering with global pharmaceutical companies, venture companies and research institutes. NSP serves as a contact point for connecting Japan/Asia and the world, developing drug candidates invented in Japan and out-licensing them to the world. In coordination with parent company, Nippon Shinyaku, Co., Ltd., NSP will first and foremost develop and supply safe and highly effective pharmaceuticals through clinical studies.

Company Details

Employees
147
Founded
-
Address
140 E Ridgewood Ave, Paramus,new Jersey 07652,united States
Phone
+1 866 677 4276
Email
in****@****rma.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Paramus, New Jersey
Looking for a particular Ns Pharma, Inc. employee's phone or email?

Ns Pharma, Inc. Questions

News

Brogidirsen (NS-089/NCNP-02) 3.5 Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2025 World Muscle Society Congress - PR Newswire

Brogidirsen (NS-089/NCNP-02) 3.5 Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2025 World Muscle Society Congress PR Newswire

NS Pharma Announces Strategic Alliance with Boston Children's Hospital to Develop New Therapies for Rare Diseases - PR Newswire

NS Pharma Announces Strategic Alliance with Boston Children's Hospital to Develop New Therapies for Rare Diseases PR Newswire

FDA Grants NS-050/NCNP-03 Rare Pediatric Disease Designation in Duchenne Muscular Dystrophy - NeurologyLive

FDA Grants NS-050/NCNP-03 Rare Pediatric Disease Designation in Duchenne Muscular Dystrophy NeurologyLive

FDA Grants Fast Track Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis - PR Newswire

FDA Grants Fast Track Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis PR Newswire

Safety and efficacy of viltolarsen in ambulatory and nonambulatory males with Duchenne muscular dystrophy - Nature

Safety and efficacy of viltolarsen in ambulatory and nonambulatory males with Duchenne muscular dystrophy Nature

FDA Grants Orphan Drug Designation to NS-051/NCNP-04 for the Treatment of Duchenne Muscular Dystrophy - PR Newswire

FDA Grants Orphan Drug Designation to NS-051/NCNP-04 for the Treatment of Duchenne Muscular Dystrophy PR Newswire

NS Pharma's Duchenne therapy Viltepso fails confirmatory trial - Fierce Pharma

NS Pharma's Duchenne therapy Viltepso fails confirmatory trial Fierce Pharma

FDA Grants Priority Review to Deramiocel for DMD Cardiomyopathy - HCPLive

FDA Grants Priority Review to Deramiocel for DMD Cardiomyopathy HCPLive

FDA Approves Viltepso for Duchenne Muscular Dystrophy - Medical Professionals Reference

FDA Approves Viltepso for Duchenne Muscular Dystrophy Medical Professionals Reference

Systemic Treatment of Body‐Wide Duchenne Muscular Dystrophy Symptoms - Wiley

Systemic Treatment of Body‐Wide Duchenne Muscular Dystrophy Symptoms Wiley

NS Pharma’s DMD Candidate Viltespo Fails Confirmatory Phase III Trial - BioSpace

NS Pharma’s DMD Candidate Viltespo Fails Confirmatory Phase III Trial BioSpace

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment - PR Newswire

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment PR Newswire

FDA Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis - PR Newswire

FDA Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis PR Newswire

NS Pharma Announces Change in Commercial Leadership - PR Newswire

NS Pharma Announces Change in Commercial Leadership PR Newswire

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment - PR Newswire

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment PR Newswire

NS Pharma Appoints New President to Oversee Next Phases of Orphan Drug Clinical Development and Commercialization - PR Newswire

NS Pharma Appoints New President to Oversee Next Phases of Orphan Drug Clinical Development and Commercialization PR Newswire

NS Pharma's Galactic53 Trial Data Is Published in Scientific Reports - PR Newswire

NS Pharma's Galactic53 Trial Data Is Published in Scientific Reports PR Newswire

NS Pharma Announces Research Alliance with MiNA Therapeutics to Develop Therapies for Rare Diseases of the Central Nervous System - PR Newswire

NS Pharma Announces Research Alliance with MiNA Therapeutics to Develop Therapies for Rare Diseases of the Central Nervous System PR Newswire

NS Pharma Shares Preliminary Results of Viltolarsen (NS-065 / NCNP-01) Phase 3 Clinical Trial (RACER53 Study) - PR Newswire

NS Pharma Shares Preliminary Results of Viltolarsen (NS-065 / NCNP-01) Phase 3 Clinical Trial (RACER53 Study) PR Newswire

Viltolarsen Approved for Duchenne Muscular Dystrophy Treatment - NeurologyLive

Viltolarsen Approved for Duchenne Muscular Dystrophy Treatment NeurologyLive

FDA news: Fast track for glioblastoma drug, breakthrough designation for leukemia therapy - Healio

FDA news: Fast track for glioblastoma drug, breakthrough designation for leukemia therapy Healio

FDA approves NS Pharma's Duchenne drug on biomarker data, just like rival Sarepta - Fierce Pharma

FDA approves NS Pharma's Duchenne drug on biomarker data, just like rival Sarepta Fierce Pharma

Top Ns Pharma, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant